Harmony Biosciences announced that the U.S. FDA granted priority review for its supplemental New Drug Application for WAKIX tablets for the treatment of excessive daytime sleepiness or cataplexy in pediatric patients 6 years of age and older with narcolepsy. The FDA has set a Prescription Drug User Fee Act, or target action date, of June 21, 2024.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on HRMY:
- Harmony Biosciences’ pitolisant designated Orphan Drug in Prader-Willi syndrome
- Harmony Biosciences price target raised to $42 from $33 at Mizuho
- Harmony Biosciences’ treatment of PWS receives FDA orphan designation
- Harmony Biosciences sees FY24 net product revenue $700M-$720M
- Harmony Biosciences sees Q4, FY23 net product revenue growth of over 30%